A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic

Psoriasis

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

J Eur Acad Dermatol Venereol.

Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barri S, Muñoz C, Llamas M, Valentí F, Josune Mitxelena M, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Manuel Carrascosa J

doi: 10.1111/jdv.16439.

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Immunodeficiency

Health-Related-Quality of Life in Common Variable Immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic

J Allergy Clin Immunol Pract.

Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Leodori G, Garzi G, Miglionico M, Tabolli S, Quinti I

doi: 10.1016/j.jaip.2020.04.003.

Psoriasis

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience

Br J Dermatol.

Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, Cazzaniga S, Malagoli P, Costanzo A

doi: 10.1111/bjd.19158.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Capturing patient-reported outcomes during the COVID-19 pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey

Arthritis Care Res (Hoboken).

Sirotich E, Dillingham S, Grainger R, Hausmann JS, COVID-19 Global Rheumatology Alliance Steering Committee.

doi: 10.1002/acr.24257.

RECOMMENDED

Atopic Dermatitis

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

J Am Acad Dermatol.

Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, Nosbaum A, Lasek A, Ferrier le Bouedec MC, Du Thanh A, Raison-Peyron N, Tetart F, Duval-Modeste AB, Misery L, Aubin F, Dompmartin A, Morice C, Droitcourt C, Soria A, Arnault JP, Delaunay J, Mahe E, Richard MA, Schoeffler A, Lacour JP, Begon E, Walter-Lepage A, Dillies AS, Rappelle-Duruy S, Barete S, Bellon N, Beneton N, Valois A, Barbarot S, Seneschal J, Staumont-Salle D

doi: 10.1016/j.jaad.2019.02.053.

Psoriasis

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments

J Am Acad Dermatol

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT

doi: 10.1016/j.jaad.2020.12.058

RECOMMENDED

Psoriasis

Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France

Ann Dermatol Venereol.

Tournier A, Khemis A, Maccari F, Reguiai Z, Bégon E, Fougerousse AC, Amy de la Breteque M, Beneton N, Parier J, Boyé T, Avenel-Audran M, Girard C, Pallure V, Perrot JL, Bastien M, Mahé E, Beauchet A; GEM Resopso

doi: 10.1016/j.annder.2018.11.011.

RECOMMENDED

Psoriasis

A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients

J Am Acad Dermatol.

Ortiz Salvador JM, Saneleuterio Temporal M, Magdaleno Tapial J, Manel VP, Conrad PM, Sahuquillo Torralba A, Mateu A, Pitarch G, Marí Ruiz JI, Mataix Díaz J, Montesinos Villaescusa E, Miralles Botella J, García Fernández L, Martorell Calatayud A, Belinchón Romero I, Sánchez Carazo JL, Pérez Ferriols A

doi: 10.1016/j.jaad.

Related content

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Health-Related-Quality of Life in Common Variable Immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience

Capturing patient-reported outcomes during the COVID-19 pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments

Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France

A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients